Drugs / KN5501
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06613490 | May → Oct 2025 overdue | antisynthetase syndrome, rheumatoid arthritis | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 0 | NCT06337474 | Aug 2024 → Jul 2025 overdue | thrombocytopenia | Changzhou No.2 People's Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06469190 | Jun 2024 → Jun 2026 overdue | — | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06318533 | Mar 2024 → Mar 2026 overdue | autoimmune disease | YANRU WANG | Recruiting | No outcome recorded |
| Phase 0 | NCT06010472 | Aug 2023 → Aug 2026 overdue | systemic lupus erythematosus | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07358988 | Jan 2026 → Jul 2027 expected | systemic lupus erythematosus | Ruitherapeutics Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN5501 | “3 infusions of anti CD19 CAR NK cells (KN5501), as well as the expansion and persistence of KN5501 in patients with refractory antisynthetase antibody syndrome (ASyS) and...” NCT06613490 ↗5“Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the "3 + 3" dose-escalation strategy.” NCT06469190 ↗ “anti-CD19 CAR NK cells (KN5501)” NCT06318533 ↗ |
| Known as | anti-CD19 CAR NK cells | “anti-CD19 CAR NK cells (KN5501)” NCT06318533 ↗ |
| Action | Deplete | “ability to deplete CD19 positive B cells” NCT06318533 ↗ |
| Modality | Cell therapy | “anti-CD19 CAR NK cells (KN5501)” NCT06318533 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07358988 ↗ |
| Target | CD19 | “anti-CD19 CAR NK cells” NCT06469190 ↗ |